Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > SBFM up 150% on mRNA oncology news

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Apr 05, 2022 11:42pm

95 Views

Post# 34579130

RE:RE:SBFM up 150% on mRNA oncology news

They have a market cap of $40mil. So if we value everything in that company at zero do we put the value on good retail engagement at $40 mil?

SPCEO1 wrote: SBFM is totally a retail thing (coupled with other brokers, algos no doubt taking advantage of those retial investors) as best I can tell. And as you can tell, that has some benefits, like when you announce pre-clincial news that sounds interesting, your stock rises by 148% and it trades 154 million shares. Maybe what they a nnounced today will one day translate into something important but it is not all that importantright now. Frankly, it is nuts but it does show how engaged retail is now in many stocks and why perhaps it is not too smart for a tiny company like TH to ignore that sector of the market when TH's share price and market cap make it pretty difficult for institutions to be interested in TH's stock.

There could be some crossover to TH when they announce their phase 1a results but, so far, I have never seen any.

What happened with SBFM today is ridiculous but it is nevertheless real. If US investors could bid up bankrupt companies by hundreds of percents after they filed for bankruptcy and informed the SEC in a public filing that shareholders would likely receive nothing, then anything is possible. There is no longer anything that can be claimed to be impossible in the financial markets - oil can trade at a negative price and trillions in government bods can hold a negative yield for years. Maybe the only thing that is still impossible is for TH to have a meaningful IR effort that is aimed at people who can actually transact in its low market cap, low priced stock.

SS1316 wrote:
Sunshine Biopharma’s Newly Designed mRNA Molecules Prove
Effective Against Multidrug Resistant Cancer Cells

Here's a Toronto Biopharma company that jumped on good news on testing alone, anyone have a take on how this may have and effect on us based on their tech? Or maybe reflect positively on the Canadian biopharma sector? Excuse my ignorance but it occurred to me that maybe people will now be looking for the next Biopharma pending good Cancer news.